RecruitingNCT07473778

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)

Sponsor

Gilead Sciences

Enrollment

3,000 participants

Start Date

Mar 17, 2026

Study Type

OBSERVATIONAL

Conditions

HIV Infections

Summary

The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cabotegravir (CAB), a drug called Emtricitabine/tenofovir alafenamide (F/TAF), and others for people with hiv infections. The study is currently recruiting participants at 10 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLenacapavir Injection

Administered via subcutaneous (SC) injection

DRUGEmtricitabine/tenofovir disoproxil fumarate (F/TDF)

Tablets administered orally

DRUGEmtricitabine/tenofovir alafenamide (F/TAF)

Tablets administered orally

DRUGCabotegravir (CAB)

Administered via intramuscular (IM) injection

DRUGLenacapavir Tablet

Administered orally

Locations(17)

Pacific Oaks Medical Group

Beverly Hills, California, United States

Family Health Centers of San Diego

San Diego, California, United States

Mills Clinical Research

West Hollywood, California, United States

Vivent Health

Denver, Colorado, United States

Bliss Health

Orlando, Florida, United States

Pineapple Healthcare Orlando

Orlando, Florida, United States

AHF - Pensacola

Pensacola, Florida, United States

Faebris Medical & Community Education

Atlanta, Georgia, United States

The Clinic NOLA

New Orleans, Louisiana, United States

Chase Brexton Health Care

Baltimore, Maryland, United States

Fenway Health

Boston, Massachusetts, United States

Be Well Medical Center

Berkley, Michigan, United States

The Aliveness Project

Minneapolis, Minnesota, United States

KC Care Health Center

Kansas City, Missouri, United States

Ohio State University Infectious Diseases Clinical Trials Unit

Columbus, Ohio, United States

Abounding Prosperity Inc.

Dallas, Texas, United States

West Virginia Health Right, Inc.

Charleston, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07473778

Related Trials

Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People

NCT058160831 location

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT041420471 location

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT066656469 locations

An Effectiveness Trial of the PrEP for WINGS Study

NCT068533141 location

Dasatinib for HIV-1 Reservoir Reduction

NCT073424913 locations